Evaluation of the Sysmex XN-31 automated analyser for blood donor malaria screening at Malawi Blood Transfusion Services.
blood donation testing
blood safety
high throughput testing
malaria and protozoal infections
patient blood management
transfusion-transmissible infections
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
06
09
2021
received:
15
06
2021
accepted:
07
09
2021
pubmed:
25
9
2021
medline:
18
3
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Balancing blood supply safety and sufficiency is challenging in malaria-endemic countries where the risk of transfusion-transmitted malaria (TTM) is ever-present. In support of reducing this risk, our study aimed at evaluating the performance of the Sysmex XN-31 analyser in blood donor malaria screening, as compared with current practice in Malawi. This prospective observational study was conducted on remnant venous donor blood samples collected at Malawi Blood Transfusion Service donation sites countrywide for routine blood-borne pathogen screening. XN-31 results were compared with routine thick smear malaria microscopy, using expert microscopy (phase 1 and 2) plus qualitative malaria polymerase chain reaction (PCR) (phase 2) to adjudicate discrepancies. XN-31 detected malaria in 614 (11.6%) of 5281 study samples compared with 341 (6.5%) for routine microscopy. Of the 273 discrepant samples, 60 smears (phase 1) could not be retrieved for expert microscopic review. Expert microscopy confirmed the XN-31 positivity in 78.8% (149/189) and 91.7% (22/24) of discrepant samples in phase 1 (n = 4416) and phase 2 (n = 975), respectively, with two cases requiring PCR testing, confirming one each as positive and negative, giving sensitivities of 100% and 75% and specificities of 99.9% and 100%, respectively, for XN-31 and routine microscopy. The automated Sysmex XN-31 analyser's high sensitivity and specificity, ability to detect all Plasmodium species and high throughput with rapid turnaround-time, overcomes many of the limitations of currently available diagnostic tests, making it well-suited for malaria screening of donated blood in malaria-endemic countries in support of TTM risk reduction.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Balancing blood supply safety and sufficiency is challenging in malaria-endemic countries where the risk of transfusion-transmitted malaria (TTM) is ever-present. In support of reducing this risk, our study aimed at evaluating the performance of the Sysmex XN-31 analyser in blood donor malaria screening, as compared with current practice in Malawi.
MATERIALS AND METHODS
METHODS
This prospective observational study was conducted on remnant venous donor blood samples collected at Malawi Blood Transfusion Service donation sites countrywide for routine blood-borne pathogen screening. XN-31 results were compared with routine thick smear malaria microscopy, using expert microscopy (phase 1 and 2) plus qualitative malaria polymerase chain reaction (PCR) (phase 2) to adjudicate discrepancies.
RESULTS
RESULTS
XN-31 detected malaria in 614 (11.6%) of 5281 study samples compared with 341 (6.5%) for routine microscopy. Of the 273 discrepant samples, 60 smears (phase 1) could not be retrieved for expert microscopic review. Expert microscopy confirmed the XN-31 positivity in 78.8% (149/189) and 91.7% (22/24) of discrepant samples in phase 1 (n = 4416) and phase 2 (n = 975), respectively, with two cases requiring PCR testing, confirming one each as positive and negative, giving sensitivities of 100% and 75% and specificities of 99.9% and 100%, respectively, for XN-31 and routine microscopy.
CONCLUSION
CONCLUSIONS
The automated Sysmex XN-31 analyser's high sensitivity and specificity, ability to detect all Plasmodium species and high throughput with rapid turnaround-time, overcomes many of the limitations of currently available diagnostic tests, making it well-suited for malaria screening of donated blood in malaria-endemic countries in support of TTM risk reduction.
Identifiants
pubmed: 34558082
doi: 10.1111/vox.13208
pmc: PMC9290921
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
346-353Subventions
Organisme : Sysmex Europe funded the study and provided the XN-31 analyser and related reagents for the study duration
Informations de copyright
© 2021 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Malar J. 2018 Feb 02;17(1):59
pubmed: 29391022
PLoS One. 2020 Nov 30;15(11):e0242507
pubmed: 33253198
Clin Infect Dis. 2013 Jun;56(12):1735-41
pubmed: 23463635
Malar J. 2019 Jan 22;18(1):15
pubmed: 30670023
Clin Infect Dis. 2010 Nov 15;51(10):1192-8
pubmed: 20929356
J Infect Dis. 2009 Nov 15;200(10):1509-17
pubmed: 19848588
Transfus Med Rev. 2005 Jul;19(3):229-40
pubmed: 16010653
Clin Microbiol Rev. 2002 Jan;15(1):66-78
pubmed: 11781267
Open Forum Infect Dis. 2019 Jun 11;6(7):ofz283
pubmed: 31334300
Malar J. 2018 Apr 16;17(1):165
pubmed: 29661200
Malar J. 2018 Jun 18;17(1):233
pubmed: 29914473
Parasitology. 2001 Jul;123(Pt 1):1-11
pubmed: 11467777
J Biomed Inform. 2014 Apr;48:193-204
pubmed: 24582925
Sci Rep. 2021 Mar 4;11(1):5268
pubmed: 33664389
Malar J. 2019 Jan 14;18(1):8
pubmed: 30642330
Malar J. 2015 Aug 07;14:306
pubmed: 26245196
Transfusion. 2013 Jul;53(7):1429-41
pubmed: 23113534
Blood Transfus. 2017 Oct;15(6):512-521
pubmed: 28488960
BMC Med. 2019 May 31;17(1):103
pubmed: 31146732
Vox Sang. 2022 Mar;117(3):346-353
pubmed: 34558082
Lancet. 2016 Apr 23;387(10029):1753-61
pubmed: 27116282
J Clin Pathol. 1994 Aug;47(8):740-2
pubmed: 7962629
Malar J. 2019 Dec 9;18(1):411
pubmed: 31818297